(NASDAQ: RIGL) Rigel Pharmaceuticals's forecast annual revenue growth rate of 23.54% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.03%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.06%.
Rigel Pharmaceuticals's revenue in 2024 is $116,882,000.On average, 4 Wall Street analysts forecast RIGL's revenue for 2024 to be $25,813,860,148, with the lowest RIGL revenue forecast at $23,921,533,557, and the highest RIGL revenue forecast at $27,166,023,079. On average, 4 Wall Street analysts forecast RIGL's revenue for 2025 to be $32,680,252,244, with the lowest RIGL revenue forecast at $28,060,449,920, and the highest RIGL revenue forecast at $34,889,661,919.
In 2026, RIGL is forecast to generate $38,474,735,152 in revenue, with the lowest revenue forecast at $35,058,024,619 and the highest revenue forecast at $40,685,898,606.